Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 11/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21755900 | 0.84 | P2RY2 (0.46) | P2RY2P2RY4POLA1SLC28A1SLC28A2 | |
| SCHEMBL767728 | 0.84 | P2RY2 (0.46) | P2RY2P2RY4POLA1SLC28A1SLC28A2 | |
| SCHEMBL16847957 | 0.83 | POLA1 (0.53) | P2RY2P2RY4POLA1SLC28A1SLC28A2 | |
| SCHEMBL12701275 | 0.82 | — | — | |
| SCHEMBL12264750 | 0.81 | TK1 (0.45) | — | |
| SCHEMBL12701434 | 0.80 | P2RY2 (0.43) | P2RY2P2RY4POLA1SLC28A1SLC28A2 | |
| SCHEMBL381881 | 0.77 | POLA1 (0.53) | P2RY2P2RY4POLA1SLC28A1SLC28A2 | |
| SCHEMBL15045907 | 0.77 | P2RY2 (0.68) | P2RY2P2RY4POLA1SLC28A1SLC28A2 | |
| SCHEMBL12701323 | 0.76 | DUT (0.43) | P2RY2P2RY4POLA1SLC28A1SLC28A2 | |
| SCHEMBL19312343 | 0.76 | CYP3A4 (0.54) | P2RY2P2RY4POLA1SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431588-B2 | Cyclopropyl polymerase inhibitors | JANSSEN PRODUCTS, LP (US) | 2013-04-30 | — | — | US | disclosed |
| US-8399429-B2 | Uracyl cyclopropyl nucleotides | JANSSEN PRODUCTS, LP (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110230436-A1 | Uracyl Cyclopropyl Nucleotides | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110092460-A1 | CYCLOPROPYL POLYMERASE INHIBITORS | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092460-A1 | CYCLOPROPYL POLYMERASE INHIBITORS | POLR2E, POLR2H, CTR9 | P2RY2 983/4885P2RY4 529/4885POLA1 106/4885 |
| US-20110230436-A1 | Uracyl Cyclopropyl Nucleotides | NUDT1, PNP, RNGTT | P2RY2 168/4885P2RY4 89/4885POLA1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.